Daphne Branham

Medicine & Life Sciences

1. Neurofibromatoses 100%
2. Glioblastoma 83%
3. cediranib 67%
4. Neurofibromatosis 1 65%
5. ErbB Receptors 49%
6. Proxy 40%
7. Consciousness 39%
8. Glioma 39%
9. Neoplasms 39%
10. Epidermal Growth Factor 38%
11. Non-Small Cell Lung Carcinoma 35%
12. Mutation 32%
13. Lymphoma 32%
14. Central Nervous System 28%
15. Brain Neoplasms 28%
16. Brain 28%
17. Neurofibrosarcoma 28%
18. Self Concept 28%
19. Neoplasm Metastasis 24%
20. Clinical Trials 22%
21. Survival 21%
22. Neurofibromatosis 2 19%
23. Schwannomatosis 19%
24. Anxiety 17%
25. Gene Amplification 15%
26. Population 14%
27. Therapeutics 14%
28. TOR Serine-Threonine Kinases 14%
29. Biopsy 14%
30. Radiation 13%
31. Phosphatidylinositol 3-Kinase 13%
32. Protein-Tyrosine Kinases 11%
33. Loneliness 11%
34. Patient Selection 11%
35. Depression 11%
36. Disease Progression 10%
37. Slit Lamp Microscopy 10%
38. Cancer Survivors 9%
39. Vascular Endothelial Growth Factor Receptor 9%
40. Spinal Puncture 9%
41. Psychological Distress 9%
42. Brain Edema 8%
43. Immunocompromised Host 8%
44. Serology 8%
45. Nerve Sheath Neoplasms 7%
46. Drug Therapy 7%
47. Principal Component Analysis 7%
48. Molecular Pathology 7%
49. Neuroimaging 7%
50. Neoplasm Genes 7%